Intriguingly, ARHGAP10 was not only downregulated in breast cancer, but was also reduced in other cancers including bladder urothelial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, esophageal carcinoma, kidney chromophobe, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, rectum adenocarcinoma, testicular germ cell tumor, uterine corpus endometrial carcinoma and uterine carcinosarcoma according to GEPIA (Tang et al., 2017) (Fig. 1D). Here, ARHGAP10 is linked to cancer.